Navigation Links
Takeda in Medical News

Healthcare Businesswomen's Association Announces 2009 Woman of the Year, Dr. Deborah Dunsire, President and CEO of Millennium: The Takeda Oncology Company

-- Event Marks 20th Anniversary of the HBA's Prestigious Industry Award -- FAIRFIELD, N.J., Feb. 17 /PRNewswire-USNewswire/ -- The Healthcare Businesswomen's Association (HBA) today announced that its 2009 "Woman of the Year" is Dr. Deborah Dunsire, President and Chief Executive Officer of M...

Welvista Announces Partnering with Takeda to Provide Medication at No Cost to the Uninsured

COLUMBIA, S.C., Feb. 11 /PRNewswire/ -- Welvista is pleased to announce it has reached an agreement with Takeda to dispense a selection of the company's medications to the uninsured through Welvista's no-cost prescription medication program. With the addition of six Takeda products, Welvista ...

Chemizon Announces Research Collaboration Expansion With Takeda

LONGMONT, Colo., Oct. 1 /PRNewswire/ -- Chemizon (010170, KOSDAQ) announced today that it has reached an agreement with Takeda Pharmaceutical Company Limited, to expand its current research collaboration focused on utilizing Chemizon's discovery platform. (Logo: http://www.newscom.com/cgi-bi...

Merck and Takeda to collaborate in the sale of Cancer drug Matuzumab

Merck Pharmaceuticals from Germany and Takeda Pharmaceuticals from Japan to colloborate in marketing of Merck's cancer drug Matuzumab. Matuzumab is developed by Merck which is in its Phase II // clinical tiral. Takeda Pharmaceuticals will sign agreement with Merck to give royalty and sale be...

Sanofi-Aventis Recognized for Workplace Efforts to Prevent Cancer

...ceuticals, GHI, GlaxoSmithKline, Jenner & Block, Johnson & Johnson, The Lance Armstrong Foundation, MD Anderson Cancer Center, Millennium: The takeda Oncology Company, Minot State University, H. Lee Moffitt Cancer Center and Research Institute, The National Cancer Institute (NCI), Novartis, The Onco...

The State of Louisiana and Together Rx Access Join Forces to Improve Prescription Access for Uninsured Residents

...ologics, Inc.; Ortho Women's Health & Urology, a Division of Ortho-McNeil Pharmaceutical, Inc.; Pfizer Inc; PriCara, a Unit of Ortho-McNeil, Inc.; takeda Pharmaceuticals North America, Inc.; Tibotec Therapeutics, a Division of Centocor Ortho Biotech Products, L.P.; and Vistakon Pharmaceuticals, LLC. ...

Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29

...ncer. Motesanib is part of a broad co-development program between Amgen and takeda and Millennium: the takeda Oncology Company. AMG 423: The Company noted it exercised its opt...

Millennium Pharmaceuticals Inc./Lymphoma Research Foundation funds lymphoma research

.... Dr. Fu will be supported by a grant of $300K over 3 years to accomplish his research project. The LRF thanks Millennium Pharmaceuticals, Inc./The takeda Oncology Company for their generous support of this grant. "We are proud to be able to support lymphoma research through grants such as this one...

CancerCare Launches New Program to Help Multiple Myeloma Patients Cover Transportation Costs

... gasoline and taxi, bus or train fare to and from their medical care. The program is funded in part by a generous grant from Millennium: The takeda Oncology Company. Cancer Care is a national non-profit organization based in New York City that provides free support services to people affected by ...

Abbott Reports Strong Second Quarter Results; Confirms Double-Digit Earnings Growth Outlook for 2009

...elated to ongoing contractual payments from takeda associated with the conclusion of the TAP joint ve...-tax) and ongoing contractual payments from takeda associated with the conclusion of the TAP j...elated to ongoing contractual payments from takeda associated with the conclusion of the TAP j...
Takeda in Medical Technology

Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer

THOUSAND OAKS, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited (TSE: 4052), today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination...

Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)

...ly 22, and OSAKA, Japan, July 23 /PRNewswire/ -- takeda Pharmaceutical Company Limited ("Takeda") today announced that takeda Global Research & Development Center, Inc., a ...n December 2007. On March 6, 2009 the FDA informed takeda that based on the December 2008 FDA Guidance title...

Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes

...6, and OSAKA, Japan, June 27, 2009 /PRNewswire/ -- takeda Pharmaceutical Company Limited ("Takeda") today announced that takeda Global Research & Development Center, Inc., a ...o diet and exercise. In recent months, the FDA and takeda have been in discussions about conducting an addit...

Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe

... OSAKA, Japan, June 3 /PRNewswire/ -- takeda Pharmaceutical Company Limited ("Takeda") announce.... With the results of this additional study, takeda expects that the MAA submissions will be made with...scovered by Takeda's wholly owned U.S. subsidiary, takeda San Diego, Inc. is a dipeptidyl peptidase IV (DPP-...

New Report by BioTrends Research Group to Highlight the Launch of ULORIC(R) (febuxostat)

... EXTON, Pa., Feb. 24 /PRNewswire/ -- BioTrends is pleased to announce the fielding of a new syndicated report, LaunchTrends(TM): Uloric (R) . takeda Pharmaceutical Company Limited announced that they received FDA approval for Uloric (R) (generic name: febuxostat) on February 13, 2009. Uloric (...

Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial

...tCall/ -- Amgen (Nasdaq: AMGN ), Millennium: The takeda Oncology Company, and its parent company takeda Pharmaceutical Company Limited (TSE:4052) today an...rds of the study population. Amgen, Millennium and takeda plan to follow this recommendation which will requ...

Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease

...Disease OSAKA, Japan, Jan. 22 /PRNewswire/ -- takeda Pharmaceutical Company Limited ("Takeda") announce...ation of vedolizumab will be the responsibility of takeda Pharmaceuticals North America, Inc., a subsidiary of takeda Pharmaceutical Company Limited....

Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma

... FRANCISCO, Dec. 8 /PRNewswire/ -- Millennium: The takeda Oncology Company today reported updated results ba...). About Millennium Millennium: The takeda Oncology Company, a leading biopharmaceutical comp.... Millennium Pharmaceuticals, Inc. was acquired by takeda Pharmaceutical Company Ltd. ("Takeda", TSE: 4502) ...

Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients

... FRANCISCO, Dec. 8 /PRNewswire/ -- Millennium: The takeda Oncology Company today reported updated results fr.... About Millennium Millennium: The takeda Oncology Company, a leading biopharmaceutical comp.... Millennium Pharmaceuticals, Inc. was acquired by takeda Pharmaceutical Company Ltd. ("Takeda", TSE: 4502) ...

Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients

... FRANCISCO, Dec. 7 /PRNewswire/ -- Millennium: The takeda Oncology Company today reported the Phase I result.... About Millennium Millennium: The takeda Oncology Company, a leading biopharmaceutical comp.... Millennium Pharmaceuticals, Inc. was acquired by takeda Pharmaceutical Company Ltd. ("Takeda", TSE: 4502) ...
Takeda in Biological News

New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers

...alled for contaminated culture to be discarded immediately. He and Folkman later developed TNP-470, a synthetic analog of fumagillin, with the help of takeda Chemical Industries in Japan (Nature, December 1990). It has shown activity against dozens of tumor types, though its mechanism of action is only part...
Takeda in Biological Technology

Takeda's Antibody Therapeutics Research Company, Takeda San Francisco, Inc. Appoints Mary Haak-Frendscho, Ph.D. as President and CSO

SAN FRANCISCO, May 22 /PRNewswire/ -- Takeda San Francisco Inc. announced today the appointment of Mary Haak-Frendscho, Ph.D., as president and chief scientific officer. Dr. Haak-Frendscho will be responsible for leading all activities at Takeda San Francisco including overall research and pre...

Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia

PALO ALTO, Calif. and OSAKA, Japan, Oct. 17 /PRNewswire/ -- Affymax, Inc. (Nasdaq: AFFY ) and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that they have been awarded the 2007 Deal of Distinction Award from the Licensing Executives Society of the U.S. and Canada (LES) for...

Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego

SAN DIEGO, Sept. 4 /PRNewswire/ -- Takeda San Diego announced today that Keith Wilson, Ph.D. has been named president and chief scientific officer (CSO). In this position, he is responsible for overseeing all activities related to Takeda San Diego, Takeda Pharmaceutical Company Limited's U.S.-...

Nanotech particles affect brain development in mice

...ice whose mothers were injected with the nanoparticles while pregnant showed alteration in gene expression related to neurological dysfunction. Ken takeda led a team of researchers from the Tokyo University of Science, Japan, who carried out the tests. He said, "Nanotechnology and the production of novel...

Sirnaomics Receives SBIR Grant from NIH/NCI for Its Multi-Targeted Lung Cancer siRNA Therapeutics

...gs. The 2006 Nobel Prize for medicine and physiology and a number of corporate acquisitions and investments by Novartis, Merck, AstraZeneca, Roche and takeda have injected billions of dollars into this novel technology and further fueled the enthusiasm for the great promise of siRNA therapeutic development....

New Report Just Published: World Prostate Cancer Therapeutics Market Report

...fi-Aventis SA, Spectrum Pharmaceuticals, Inc., and takeda Pharmaceutical Company Limited. Market data and an...gh Terminates Collaboration with Novacea II-68 takeda Terminates JV Deal, Merges its Subsidiaries II-68 ... II-71 Cell Genesys Forms Global Alliance with takeda on GVAX Immunotherapy Development for Prostate...

Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief Medical Officer

...n from IDM Pharma, which was recently purchased by takeda Pharmaceuticals Limited, where he led the clinical...an served as vice president of clinical science at takeda Global Research & Development Center, Inc., a subsidiary of takeda Pharmaceutical Company Limited, where he was focus...

Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team

... of Proteolix's Board of Directors, was a clinical developer of the proteasome inhibitor VELCADE(R) at Millennium Pharmaceuticals (now a subsidiary of takeda Pharmaceutical Company). As CMO, he will be responsible for the advancement of carfilzomib, Proteolix's lead anti-cancer proteasome inhibitor for the...

Catalyst Biosciences Expands Scientific Advisory Board With Leading Experts in Protease Therapeutic Discovery and Development

...and consulted for a variety of biotech and pharmaceutical companies including GlaxoSmithKline, Karo Bio, Monsanto, Pfizer, Pharmacia, Searle, SPRL and takeda Pharmaceuticals. Professor Fletterick received his Ph.D. from Cornell University and did his postdoctoral research in molecular biophysics in the l...

FDA Approves ULORIC(R) (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout

...ore than 40 years, marking second FDA approval for takeda within one month DEERFIELD, Ill., and OSAKA, Japan, Feb. 13 /PRNewswire/ -- takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, takeda Pharmaceuticals North America, Inc., announced tod...
Other Tags
(Date:7/11/2014)... Europe Well Intervention Market report defines and segments the well ... The well intervention services market in Europe is estimated to ... by 2018, at a CAGR of 7% from 2013 to ... Intervention Market report, to get an idea of the in-depth ... in the Europe well intervention market, and is supported by ...
(Date:7/11/2014)... News) -- In people with sex addiction, pornography affects ... seen in drug addicts as they consume drugs, a ... brain activity between patients who have compulsive sexual behavior ... addicts," study author Dr. Valerie Voon, of the University ... release. Voon,s research involved 19 men with sex ...
(Date:7/11/2014)... The report “Probiotics Market by Products (Functional ... (Regular, Therapeutic, Preventive Health Care) & Ingredients (Lactobacilli, ... 2019 ” defines and segments the global probiotics ... market value of probiotic products and ingredients. The ... for the global market with an analysis of ...
(Date:7/11/2014)... 2014 Biostimulants are widely applied in ... and ornamentals. These also help turf and ornamentals in ... roots. Turf, ornamentals, and flowers appear healthy and strong ... has increased from the last few years. The most ... is Europe, with around 40% share in 2013, and ...
(Date:7/11/2014)... 2014) Obese and overweight firefighters are not ... providers, according to new research from The University ... , National guidelines state that health care professionals ... maintaining a healthy weight. Firefighters have high rates ... cause of line-of-duty deaths in firefighters. This study ...
Breaking Medicine News(10 mins):Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3
(Date:7/10/2014)... , July 2, 2014  Unisys Corporation,s (NYSE: ... Unisys Nederland N.V., today announced that it has been selected ... and manage a new Basic Provision Biometrics solution for penitentiaries ... Unisys won the contract with a solution based on its ... The term of the contract is up to seven years, ...
(Date:7/10/2014)... 3, 2014 According to the ... (Swipe And Area), Material (Optical Prism, Pizeoelectric, Capacitive, and ... and Banking & Finance), and Geography - Global Trends ... the global Fingerprint Sensors Market is projected to cross ... of 16.8% from 2014 to 2020. Browse ...
(Date:7/10/2014)... New York , July 7, 2014 ... by Transparency Market Research "Electronic Access Control Systems Market ... 2014 - 2019," the global Electronic Access Control systems ... and is expected to grow at a CAGR of ... value of USD 31,187.8 million in 2019. ...
Breaking Biology News(10 mins):Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5
Other Contents